Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2251 to 2265 of 9128 results

  1. Encorafenib with cetuximab and FOLFOX for untreated BRAF V600E mutation-positive metastatic colorectal cancer [ID6734]

    Awaiting development Reference number: GID-TA11961 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Camizestrant for treating oestrogen receptor-positive HER2-negative early breast cancer at risk of recurrence after 2 to 5 years of adjuvant endocrine treatment [TSID12348]

    Awaiting development Reference number: GID-TA11971 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [ID1259]

    In development Reference number: GID-TA10225 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277]

    In development Reference number: GID-TA10248 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]

    In development Reference number: GID-TA10250 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]

    In development Reference number: GID-TA10251 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Renal sympathetic denervation for resistant hypertension: draft scope consultation

    We are listening to your views on this HealthTech guidance. Comments close 29 June 2026.

    In consultation

  8. Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver: interventional procedure consultation

    We are listening to your views on this HealthTech guidance. Comments close 7 July 2026.

    In consultation

  9. Blood-based biomarker tests for surveillance in people at risk of hepatocellular carcinoma: draft scope consultation

    We are listening to your views on this HealthTech guidance. Comments close 6 July 2026.

    In consultation

  10. Digital technologies to support home monitoring of vision changes for people with advanced dry age-related macular degeneration: early-use assessment: draft guidance

    We are listening to your views on this HealthTech guidance. Comments close 6 July 2026.

    In consultation

  11. Topical tapinarof for treating atopic dermatitis in people 2 years and over ID6713: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 1 July 2026.

    Technology appraisal guidance
    In consultation

  12. Topical tapinarof for treating mild to severe plaque psoriasis ID6712: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 30 June 2026.

    Technology appraisal guidance
    In consultation

  13. Software with artificial intelligence (AI)-derived algorithms to help interpret electroencephalograms (EEGs) for suspected epilepsy: early-use assessment: draft guidance

    We are listening to your views on this HealthTech guidance. Comments close 30 June 2026.

    In consultation

  14. Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [ID6529]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 30 June 2026.

    Technology appraisal guidance
    In consultation

  15. Teclistamab for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6628: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 29 June 2026.

    Technology appraisal guidance
    In consultation